Wen-Kai Weng, MD, PhD
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood & Marrow Transplantation 875 Blake Wilbur Dr Clinic C MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-8950
- Academic Offices
Personal Information Email Tel (650) 723-7689Alternate Contact Janice Smith Administrative Associate Email Tel Work 650-724-4155Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Lymphoma
- Cutaneous T-Cell Lymphoma
- Medical Oncology
- Myeloma
Administrative Appointments
- Scientific Advisory Board, Lymphoma Research Foundation (2011 - present)
Honors and Awards
- Division Teaching Award, BMT, Stanford University (2012)
- Developmental Research Award, Stanford Cancer Institute (2012-2013)
- ITI Seed Grant Award, Institute for Immunity, Transplantation and Infection, Stanford University (2011-2012)
- Division Teaching Award, BMT, Stanford University (2010)
- Developmental Research Award, Stanford University Cancer Center (2009-2010)
- Division Teaching Award, BMT, Stanford University (2009)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2008) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2007) |
| Fellowship: | Stanford University School of Medicine CA (2002) |
| Residency: | University of Texas Medical School at Houston, Internal Medicine (1999) |
| Internship: | University of Texas Medical School TX (1997) |
| Doctorate Degree: | University Of Minnesota MN (1996) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
My clinical focus is non-Hodgkin's lymphoma (NHL) and am currently conducting clinical trials with novel therapies on these patients. My basic research interest is immunotherapy for lymphoma, with two components: tumor vaccines and allogeneic transplant. For the tumor vaccine, I am working with my colleagues in Oncology to conduct a clinical trial using a CpG-activated tumor vaccine in mantel cell NHL patients who undergo autologous transplantation. The goal is to sensitize the autologous T cells to recognize the malignant lymphoma cells and to expand these tumor-specific T cells immediate after autologous transplant.
Second, I am conducting a study using a novel non-myeloablative preparative regimen prior to allogeneic transplant in patients with mycosis fungoides/Sezary syndrome, a cutaneous T cell NHL. While these patients exhibit little sensitivity to traditional chemotherapy, graft-versus-lymphoma effect provided by allogeneic transplant seems to have an excellent disease control effect. I also use high throughput sequencing technology to assess the minimal residual disease and the immune reconstitution after allogeneic transplant.
Clinical Trials
- Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
- Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
- Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
- Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
- Recruiting Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Publications
- Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant. 2013; (1 Suppl): S97-S101
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012; (3): 1066-75
- Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant. 2012; (4): 516-21
- The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012; (4): 354-60
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
Help